... pathogenic CoVs, in the case of SARS-CoV there remains the threat of introducinglive virus into the environment from partially inactivatedvaccine, as there are no validated and effective inactiva-tion ... term,necessitating periodic boosting, which in the end may notbe sufficient to prevent re-infection.Despite these potential pitfalls in the development of ahuman vaccine, efforts to develop a vaccine to ... SARS-CoV inactivated by beta-propiolactone was used as anti-gen in mice and rabbits, the animals elicited antibodiesagainst the receptor-binding domain (RBD) present in the S1 region of SARS-CoV. These...